Literature DB >> 32840200

Use of Ov16-Based Serology for Post-Elimination Surveillance of Onchocerciasis in Ecuador.

Ángel Guevara1, Esteban Salazar1,2,3, Yosselin Vicuña1, Hassan K Hassan4, Antonio Muro3, Ronald Guderian5, Philip J Cooper6,7, Thomas R Unnasch4.   

Abstract

Onchocerciasis is a blinding disease caused by the filarial parasite Onchocerca volvulus, with a worldwide distribution. Onchocerciasis has been targeted for regional elimination based on annual and semiannual mass drug administration (MDA) with ivermectin in endemic communities over several years. This strategy in Ecuador led to the interruption of transmission and suspension of ivermectin MDA in 2009 with certification of elimination in 2014. In the present study, we analyzed sera collected in 2018 from 123 children aged 5-9 years from formerly hyperendemic communities in the Esmeraldas focus, Ecuador, for the presence of antibodies to Ov16 antigen. All samples were negative, indicating no evidence of transmission since MDA was stopped. Ov16-based serology offers an economic and practical alternative for measuring vector infectivity for post-certification surveillance in formerly endemic countries where expertise and capacity to reliably measure fly infectivity rates are costly to maintain.

Entities:  

Mesh:

Year:  2020        PMID: 32840200      PMCID: PMC7543846          DOI: 10.4269/ajtmh.20-0082

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   3.707


  8 in total

1.  Field applicability of a rapid-format anti-Ov-16 antibody test for the assessment of onchocerciasis control measures in regions of endemicity.

Authors:  Ettie M Lipner; Noumouza Dembele; Sanou Souleymane; William Soumbey Alley; D Rebecca Prevots; Laurent Toe; Boayke Boatin; Gary J Weil; Thomas B Nutman
Journal:  J Infect Dis       Date:  2006-06-14       Impact factor: 5.226

2.  681 Progress report on the elimination of human onchocerciasis, 2016–2017.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2017-11-10

3.  An immunogenic Onchocerca volvulus antigen: a specific and early marker of infection.

Authors:  E Lobos; N Weiss; M Karam; H R Taylor; E A Ottesen; T B Nutman
Journal:  Science       Date:  1991-03-29       Impact factor: 47.728

4.  Progress toward elimination of onchocerciasis in the Americas.

Authors:  Mauricio Sauerbrey; Lindsay J Rakers; Frank O Richards
Journal:  Int Health       Date:  2018-03-01       Impact factor: 2.473

5.  Interruption of infection transmission in the onchocerciasis focus of Ecuador leading to the cessation of ivermectin distribution.

Authors:  Raquel Lovato; Angel Guevara; Ronald Guderian; Roberto Proaño; Thomas Unnasch; Hipatia Criollo; Hassan K Hassan; Charles D Mackenzie
Journal:  PLoS Negl Trop Dis       Date:  2014-05-22

6.  Post-elimination surveillance in formerly onchocerciasis endemic focus in Southern Mexico.

Authors:  Nadia A Fernández-Santos; Thomas R Unnasch; Isabel C Rodríguez-Luna; Francisco Gibert Prado-Velasco; Adebiyi A Adeniran; Humberto Martínez-Montoya; Mario A Rodríguez-Pérez
Journal:  PLoS Negl Trop Dis       Date:  2020-01-30

7.  Impact of long-term treatment of onchocerciasis with ivermectin in Ecuador: potential for elimination of infection.

Authors:  Juan Carlos Vieira; Philip J Cooper; Raquel Lovato; Tamara Mancero; Jorge Rivera; Roberto Proaño; Andrea A López; Ronald H Guderian; José Rumbea Guzmán
Journal:  BMC Med       Date:  2007-05-23       Impact factor: 8.775

8.  Elimination of onchocerciasis in Ecuador: findings of post-treatment surveillance.

Authors:  Ángel Guevara; Raquel Lovato; Roberto Proaño; Mario A Rodriguez-Perez; Thomas Unnasch; Philip J Cooper; Ronald H Guderian
Journal:  Parasit Vectors       Date:  2018-04-24       Impact factor: 3.876

  8 in total
  1 in total

1.  Evaluation of antibody serology to determine current helminth and Plasmodium falciparum infections in a co-endemic area in Southern Mozambique.

Authors:  Rebeca Santano; Rocío Rubio; Berta Grau-Pujol; Valdemiro Escola; Osvaldo Muchisse; Inocência Cuamba; Marta Vidal; Gemma Ruiz-Olalla; Ruth Aguilar; Javier Gandasegui; Maria Demontis; Jose Carlos Jamine; Anélsio Cossa; Charfudin Sacoor; Jorge Cano; Luis Izquierdo; Chetan E Chitnis; Ross L Coppel; Virander Chauhan; David Cavanagh; Sheetij Dutta; Evelina Angov; Lisette van Lieshout; Bin Zhan; José Muñoz; Carlota Dobaño; Gemma Moncunill
Journal:  PLoS Negl Trop Dis       Date:  2022-06-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.